Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
RELA/NFκB p65 Lentiviral Activation Particles (h): sc-400004-LAC
- Target species: human
- 200 µl of transduction-ready, high-titer CRISPR/dCas9 Lentiviral Activation Particles
- RELA/NFκB p65 Lentiviral Activation Particles (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically and efficiently upregulate gene expression via lentiviral transduction of cells
- RELA/NFκB p65 Lentiviral Activation Particles (h) contain the following SAM Activation elements: a deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, an MS2-p65-HSF1 fusion protein and a target-specific 20 nt guide RNA. They also contain the blasticidin, hygromycin and puromycin resistance genes
- Upon transduction, the SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by RELA/NFκB p65 Lentiviral Activation Plasmid (h) and RELA/NFκB p65 Lentiviral Activation Plasmid (h2) target distinct regulatory regions of the RELA promoter. One or both designs may be available
- Following transfection, gene activation efficiency can be assayed by WB, IF or IHC using antibody: RELA/NFκB p65 Antibody (F-6): sc-8008
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
RELA/NFκB p65 Lentiviral Activation Particles (h) | sc-400004-LAC | 200 µl | $455.00 |
RELA encodes the p65 (RelA) subunit of NFκB, a central transcription factor that integrates signals from cytokine receptors, pattern-recognition receptors, antigen receptors, and cellular stress pathways. Upon IκB degradation, p65 translocates to the nucleus to regulate genes controlling inflammation, innate and adaptive immunity, cell survival, proliferation, and differentiation. NFκB p65 activity is shaped by post-translational modifications and crosstalk with pathways such as TNF, IL-1, TLR, MAPK, and JAK/STAT to tune transcriptional outputs. Dysregulated RELA signaling is associated with chronic inflammatory states and is frequently implicated in oncogenic programs that enhance survival, immune evasion, and therapy resistance in diverse tumor contexts.
RELA/NFκB p65 Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient RELA upregulation across a broader range of human cell types.
RELA/NFκB p65 Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the RELA transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous RELA/NFκB p65 expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native RELA genomic locus and regulatory architecture.
The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.